ownload GRP3 mediates the activation of the Ras signaling pathway that is present in many human cancers. Here, lored the involvement of RasGRP3 in the formation and maintenance of the prostate cancer phenotype. P3 expression was elevated inmultiple human prostate tumor tissue samples and in the human androgenndent prostate cancer cell lines PC-3 and DU 145 compared with the androgen-dependent p...

nloaded GRP3 mediates the activation of the Ras signaling pathway that is present in many human cancers. Here, lored the involvement of RasGRP3 in the formation and maintenance of the prostate cancer phenotype. P3 expression was elevated inmultiple human prostate tumor tissue samples and in the human androgenndent prostate cancer cell lines PC-3 and DU 145 compared with the androgen-dependent p...

We find that the prostate cancer cell lines ALVA-31, PC-3, and DU 145 are highly sensitive to apoptosis induced by TRAIL (tumor-necrosis factor-related apoptosis-inducing ligand), while the cell lines TSU-Pr1 and JCA-1 are moderately sensitive, and the LNCaP cell line is resistant. LNCaP cells lack active lipid phosphatase PTEN, a negative regulator of the phosphatidylinositol (PI) 3-kinase/Akt...

We studied the molecular mechanisms of apoptosis in the prostate cancer cell line LNCaP and whether overexpression of caspase activity could force this cell line to undergo apoptosis. The inhibitor of phosphomevalonate decarboxylase, sodium phenylacetate, and the protein kinase inhibitor staurosporine induced (a) release of cytochrome c from the mitochondria to the cytosol; (b) reduction in mit...

Responses to androgen vary widely among prostate cancers and prostatic carcinoma cell lines. We have explored the basis for this heteroge neity by examining the levels of androgen receptor expression in a prostate carcinoma cell line (LNCaP) that expresses the androgen recep tor and two prostate carcinoma cell lines that do not contain detectable androgen receptor. We find that while the LNCaP ...

Responses to androgen vary widely among prostate cancers and prostatic carcinoma cell lines. We have explored the basis for this heteroge neity by examining the levels of androgen receptor expression in a prostate carcinoma cell line (LNCaP) that expresses the androgen recep tor and two prostate carcinoma cell lines that do not contain detectable androgen receptor. We find that while the LNCaP ...

Responses to androgen vary widely among prostate cancers and prostatic carcinoma cell lines. We have explored the basis for this heterogeneity by examining the levels of androgen receptor expression in a prostate carcinoma cell line (LNCaP) that expresses the androgen receptor and two prostate carcinoma cell lines that do not contain detectable androgen receptor. We find that while the LNCaP ce...